WebIntroduction: DARA is a human IgGκ monoclonal antibody targeting CD38 and is approved for intravenous (IV) infusion across lines of therapy for MM. In phase 3 clinical studies, … WebDec 3, 2013 · Leleu X, Beksac M, Chou T, Dimopoulos M, Yoon SS, Prince HM, Pour L, Shelekhova T, Chari A, Khurana M, Zhang J, Obreja M, Qi M, Oriol A, Siegel D. Efficacy …
Advances in oral mesenchymal stem cell-derived ... - ScienceDirect
WebDec 28, 2024 · Chari A, Lonial S, Mark TM, et al. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple … WebDec 19, 2024 · growth charts infant boy
Author notes - American Society of Hematology
WebJul 19, 2024 · Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2024;134:421–431. Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients … WebMar 4, 2024 · Blood. 2024; 134: 421-431. Crossref; ... Our results replicated the findings reported by Chari et al. 18. Chari A. Mark T.M. Krishnan A. et al. Use of Montelukast to … Web1. Introduction. Citation 1]. MM is more common in the elderly [Citation 1 – Citation 4].In the US, the median age at diagnosis is 69 years, with the majority of individuals diagnosed … growth chart who